Inhibrx Biosciences, Inc. (INBX) Financials

$11.18

south_east
-$0.09 (-0.76%)
Day's range
$11.15
Day's range
$11.87
$2B$2B$1.5B$1.5B$1B$1B$500M$500M$0$0-$500M-$500MEarning201820182019201920202020202120212022202220232023202420241800000%1800000%1400000%1400000%1000000%1000000%600000%600000%200000%200000%-200000%-200000%Profit Margin
Profit Margin
Revenue
Earnings

INBX Income statement / Annual

Last year (2024), Inhibrx Biosciences, Inc.'s total revenue was $200,000.00, a decrease of 88.89% from the previous year. In 2024, Inhibrx Biosciences, Inc.'s net income was $1.69 B. See Inhibrx Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Operating Revenue $200,000.00 $1.80 M $2.18 M $7.13 M $12.81 M $9.09 M $7.50 M $7.95 M $6.67 M
Cost of Revenue $2.29 M $1.19 M $2.85 M $2.69 M $73.50 M $47.91 M $33.45 M $25.51 M $16.99 M
Gross Profit -$2.09 M $609,000.00 -$668,000.00 $4.44 M -$60.69 M -$38.81 M -$25.95 M -$17.56 M -$10.33 M
Gross Profit Ratio -10.43 0.34 -0.31 0.62 -4.74 -4.27 -3.46 -2.21 -1.55
Research and Development Expenses $203.74 M $190.65 M $110.19 M $71.44 M $73.50 M $47.91 M $33.45 M $25.51 M $16.99 M
General & Administrative Expenses $127.91 M $29.38 M $21.12 M $12.36 M $6.84 M $9.02 M $4.65 M $2.61 M $1.82 M
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 -$253,000.00
Selling, General & Administrative Expenses $127.91 M $29.38 M $21.12 M $12.36 M $6.84 M $9.02 M $4.65 M $2.61 M $1.57 M
Other Expenses $0.00 $0.00 -$14,000.00 -$106,000.00 -$80,000.00 -$4.12 M $68,000.00 $24,000.00 $0.00
Operating Expenses $331.65 M $219.83 M $131.30 M $83.69 M $80.25 M $52.81 M $37.01 M $27.68 M $18.56 M
Cost And Expenses $331.65 M $221.02 M $131.30 M $83.69 M $80.25 M $52.81 M $37.01 M $27.68 M $18.81 M
Interest Income $10.94 M $11.92 M $16.11 M $5.22 M $10.82 M $5.72 M $0.00 $0.00 $759,000.00
Interest Expense $13.49 M $31.84 M $16.11 M $5.22 M $10.82 M $5.72 M $1.48 M $2.13 M $0.00
Depreciation & Amortization $2.29 M $1.19 M $1.23 M $2.69 M $2.39 M $2.52 M $676,000.00 $399,000.00 $253,000.00
EBITDA $1.70 B -$206.69 M -$125.82 M -$76.56 M -$67.44 M -$42.60 M -$28.77 M -$19.31 M -$11.89 M
EBITDA Ratio 8516.75 -114.83 -57.77 -10.75 -5.27 -4.69 -3.84 -2.43 -1.78
Operating Income Ratio -1657.24 -121.79 -59.28 -10.75 -5.27 -4.81 -3.94 -2.48 -1.82
Total Other Income/Expenses Net $2.02 B -$20.50 M -$29.90 M -$5.20 M -$8.19 M -$6.79 M -$1.41 M -$2.10 M -$739,000.00
Income Before Tax $1.69 B -$239.72 M -$145.22 M -$81.77 M -$75.63 M -$50.50 M -$30.93 M -$21.83 M -$12.89 M
Income Before Tax Ratio 8437.87 -133.18 -66.68 -11.48 -5.91 -5.55 -4.12 -2.75 -1.93
Income Tax Expense $2,000.00 $3,000.00 $3,000.00 $2,000.00 $3,000.00 $898,000.00 $96,000.00 $250,000.00 -$4.62 M
Net Income $1.69 B -$241.36 M -$145.23 M -$81.77 M -$75.64 M -$51.40 M -$31.16 M -$19.44 M -$8.27 M
Net Income Ratio 8437.86 -134.09 -66.68 -11.48 -5.91 -5.65 -4.16 -2.45 -1.24
EPS 114.01 -5.12 -3.62 -2.15 -2.99 -1.41 -1.15 -0.68 -0.23
EPS Diluted 112.62 -5.12 -3.62 -2.15 -2.99 -1.41 -1.15 -0.68 -0.23
Weighted Average Shares Out $14.48 M $47.13 M $40.11 M $38.01 M $25.26 M $36.55 M $27.08 M $28.79 M $36.55 M
Weighted Average Shares Out Diluted $14.48 M $47.13 M $40.11 M $38.01 M $25.26 M $36.55 M $27.08 M $28.79 M $36.55 M
Link